WGµç×Ó¹ÙÍø

ΪÁ˸üºÃµÄä¯ÀÀЧ¹û £¬£¬£¬£¬£¬£¬£¬½¨ÒéʹÓÃChromeä¯ÀÀÆ÷Éó²é¡£¡£¡£¡£¡£

ÖªµÀÁË

ΪÑàÎÑÐÐÒµ×¢ÈëÉúÆø£¡¹ãÖÝÖÐÒ½Ò©´óѧÍŽáWGµç×Ó¹ÙÍøÊÖÒÕÍŶÓÐû²¼ÑàÎѹ¦Ð§Ö÷Òª¿ÆÑÐЧ¹û

2022-03-03
       ½üÄêÀ´ £¬£¬£¬£¬£¬£¬£¬µ³ÖÐÑëÌá³ö“Á¢Ò졢Эµ÷¡¢ÂÌÉ«¡¢¿ª·Å¡¢¹²Ï픵ÄÐÂÉú³¤ÀíÄî £¬£¬£¬£¬£¬£¬£¬Íƶ¯¾­¼Ã¸ßÖÊÁ¿Éú³¤ £¬£¬£¬£¬£¬£¬£¬¸üºÃµØÊ©Õ¹ÔÚÐÂʱÆÚË¢ÐÂÁ¢ÒìµÄÒýÁì×÷Óᣡ£¡£¡£¡£ÔÚ´ËÅä¾°Ï £¬£¬£¬£¬£¬£¬£¬´«³ÐÓ¢»ª £¬£¬£¬£¬£¬£¬£¬ÊØÕýÁ¢Òì £¬£¬£¬£¬£¬£¬£¬Íƶ¯ÖÐʽ×̲¹ÐÐÒµ¸ßÖÊÁ¿Éú³¤ £¬£¬£¬£¬£¬£¬£¬³ÉΪÑàÎÑÐÐÒµÉú³¤µÄÐÂÒªÇ󡣡£¡£¡£¡£
 
       ÖÐʽ×̲¹ÎÄ»¯ÊÇÖйú¹Å°åÎÄ»¯¹å±¦µÄÒ»²¿·Ö £¬£¬£¬£¬£¬£¬£¬Ëæ×ž­¼ÃˮһÉú³¤ÓëÃñ×寷ůÔÙÆð £¬£¬£¬£¬£¬£¬£¬Ô½À´Ô½¶àÏûºÄÕßÇàíùÖÐʽ×̲¹µÄÑøÉú·½·¨¡£¡£¡£¡£¡£24Äêרע¸ßÆ·ÖÊÑàÎÑ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø¸ß¶ÈÖØÊÓÑз¢Á¢ÒìÊÂÇé £¬£¬£¬£¬£¬£¬£¬Ò»Ö±ÖÂÁ¦ÓÚÓÃÏÖ´ú¿ÆÑпªÕ¹¶ÔÑàÎѵÄÉîÈëÑо¿ £¬£¬£¬£¬£¬£¬£¬¾ò¿ÍÑàÎѵÄÓªÑø¼ÛÖµºÍ¹¦Ð§¡£¡£¡£¡£¡£Í¨¹ýÆ·ÀàÁ¢Òì¡¢¹¤ÒÕÁ¢Òì¡¢¿ÆÑÐÁ¢Òì¡¢ÌåÑéÁ¢Òì £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÇÐʵ½â¾öÏûºÄÕßÑàÎÑ×̲¹Í´µã £¬£¬£¬£¬£¬£¬£¬ÔÚÀ©´óÆ·ÅÆÓ°ÏìÁ¦µÄͬʱ £¬£¬£¬£¬£¬£¬£¬Íƶ¯×ÅÐÐÒµÕýÏòÉú³¤¡£¡£¡£¡£¡£
 
       ÎªÉý¼¶ÑàÎÑÆ·ÖÊ £¬£¬£¬£¬£¬£¬£¬Íƶ¯ÑàÎѵĻù´¡Ñо¿ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÑз¢ÖÐÐĽ¨ÉèÑàÎÑÑо¿Ôº £¬£¬£¬£¬£¬£¬£¬ÓÉÖйú¹¤³ÌÔº¡¢ÖпÆÔºµÄר¼ÒԺʿ £¬£¬£¬£¬£¬£¬£¬ÒÔ¼°À´×Ô½­ÄÏ´óѧµÈ¶àλ×ÅÃû¸ßУ»£»£»£»£» £»ú¹¹×¨¼Ò½ÌÊÚ £¬£¬£¬£¬£¬£¬£¬×é³ÉѧÊõίԱ»á £¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÍÆ¶¯ÑàÎѵĻù´¡Ñо¿¡¢ÒÔ¼°ÓªÑø¹¦Ð§µÈ¿ÆÑ§ÁìÓòµÄ¿ÆÑÐÔ˶¯¡£¡£¡£¡£¡£±ðµÄ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø½èÖú¸ßУµÄרҵÓÅÊÆÒ»Ö±ÌáÉýÑàÎѲúÆ·Æ·ÖÊÓë¿ÆÑÐˮƽ £¬£¬£¬£¬£¬£¬£¬È¥Äê12Ô £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÐ¯ÊÖ½­ÄÏ´óѧ £¬£¬£¬£¬£¬£¬£¬¿ªÆô“²ú¡¢Ñ§¡¢ÑДÉî¶ÈÏàÖú £¬£¬£¬£¬£¬£¬£¬²¢ÉèÁ¢“½­ÄÏ´óѧʳÎïѧԺWGµç×Ó¹ÙÍø¿Æ´´¾ºÈü»ù½ð” £¬£¬£¬£¬£¬£¬£¬ÅäºÏÏàÖúÔö½øÑàÎÑÑз¢µÄ¸ßÖÊÁ¿Éú³¤¡£¡£¡£¡£¡£
 

WGµç×Ó(ÖйúÇø)-¹Ù·½ÍøÕ¾
ͼ£º“½­ÄÏ´óѧʳÎïѧԺWGµç×Ó¹ÙÍø¿Æ´´¾ºÈü»ù½ð”½ÒÅÆÒÇʽ

 
      WGµç×Ó¹ÙÍø×¢ÖØ×ÔÖ÷Á¢ÒìÄÜÁ¦µÄ½¨Éè £¬£¬£¬£¬£¬£¬£¬²»µ«¾ß±¸ÐÂÈ˲ŵÄ×÷ÓýÄÜÁ¦ £¬£¬£¬£¬£¬£¬£¬Í¬Ê±ÒԿƼ¼¸³ÄÜ £¬£¬£¬£¬£¬£¬£¬ÒÔ¿ÆÑÐӲʵÁ¦ÖúÍÆÑàÎѹ¤ÒµÍɱäÉý¼¶¡£¡£¡£¡£¡£½ñÄê2Ô £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø¾­Óɸ£½¨Ê¡¹¤ÐžֶÔWGµç×Ó¹ÙÍøÑàÎÑÑо¿ÔºÊÖÒÕʵÁ¦ÆÀ¶¨ £¬£¬£¬£¬£¬£¬£¬ÀֳɻñÅú“µÚÈýÊ®¶þÅúÊ¡ÆóÒµÊÖÒÕÖÐÐÄ”³Æºô £¬£¬£¬£¬£¬£¬£¬²¢ÔÚ2ÔÂ22ÈÕ £¬£¬£¬£¬£¬£¬£¬ÀֳɾÙÐÐWGµç×Ó¹ÙÍøÑàÎÑÑо¿Ôº“¸£½¨Ê¡ÆóÒµÊÖÒÕÖÐÐÄ”½ÒÅÆÒÇʽ¡£¡£¡£¡£¡£
 

WGµç×Ó(ÖйúÇø)-¹Ù·½ÍøÕ¾
ͼ£ºWGµç×Ó¹ÙÍøÑàÎÑÑо¿Ôº“¸£½¨Ê¡ÆóÒµÊÖÒÕÖÐÐÄ”½ÒÅÆÒÇʽ 


       ÒÔÁ¢ÒìÖýÔìÓ²ºË¿ÆÑÐʵÁ¦ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÈ¡µÃÁ˷ḻµÄÑо¿Ð§¹û¡£¡£¡£¡£¡£2021Äê12Ô £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÑàÎÑÑо¿ÔººÍ½­ÄÏ´óѧʳÎï¿ÆÑ§ÓëÊÖÒÕ¹ú¼ÒÖØµãʵÑéÊÒЯÊÖÍê³É²¢¿¯µÇÁËרҵÑо¿Ð§¹û¡¶Ê³ÓÃÑàÎÑÏû»¯ÎïµÄƤ·ôÃÀ°×»îÐÔÑо¿£ºÒ»ÖÖð¤ÂѰ×ÌÇÂѰס· £¬£¬£¬£¬£¬£¬£¬ÊµÑéÅú×¢£º“ÑàÎÑëÄÊÇÆäÖÐÖ÷ÒªµÄ¿¹Ñõ»¯ÒòËØ £¬£¬£¬£¬£¬£¬£¬Ð¢Ë³ÂÊΪ85.87% £¬£¬£¬£¬£¬£¬£¬ÊʺϿª·¢ÐÂÒ»´úÃÀ°×±£½¡Æ·¡£¡£¡£¡£¡£”
 
       ¿ËÈÕ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÊÖÒÕÍŶӺ͹ãÖÝÖÐÒ½Ò©´óѧÊÖÒÕÍÅ¶Ó £¬£¬£¬£¬£¬£¬£¬·¢Ã÷ÑàÎѸ¨ÖúÖÎÁƽ᳦Ñ׵Ĺ¦Ð§ £¬£¬£¬£¬£¬£¬£¬²¢Ðû²¼ÓÚ¡¶Frontiers in Pharmacology¡· £¬£¬£¬£¬£¬£¬£¬2021 £¬£¬£¬£¬£¬£¬£¬4£¨12£© £¬£¬£¬£¬£¬£¬£¬Article 632602¡£¡£¡£¡£¡£Ñо¿½áÂÛÅú×¢£º“ EBN improved symptoms of colitis, reduced colonic injury, and inhibited the increases in the levels of the pro-inflammatory cytokines IL-1β and TNF-α.”£¨Ê³ÓÃÑàÎѸÄÉÆÁËÈ´³¦Ñ×Ö¢×´ £¬£¬£¬£¬£¬£¬£¬¼õÇáÁËÈ´³¦ËðÉË £¬£¬£¬£¬£¬£¬£¬²¢ÒÖÖÆÁË´ÙÑ×ϸ°ûÒò×ÓIL-1βºÍTNF-αˮƽµÄÉý¸ß¡£¡£¡£¡£¡££©”¸Ã¹¦Ð§µÄ·¢Ã÷½øÒ»²½ÍØ¿íÁËÑàÎѲúÆ·µÄÓ¦Óó¡¾° £¬£¬£¬£¬£¬£¬£¬¸¶ÓëÑàÎÑÐÐÒµ¸ü¶àµÄ¿ÉÄÜÐÔ¡£¡£¡£¡£¡£
 

WGµç×Ó(ÖйúÇø)-¹Ù·½ÍøÕ¾
ͼ£ºWGµç×Ó¹ÙÍøÊÖÒÕÍŶӺ͹ãÖÝÖÐÒ½Ò©´óѧÊÖÒÕÍŶÓ
“·¢Ã÷ÑàÎѸ¨ÖúÖÎÁƽ᳦Ñ׵Ĺ¦Ð§”µÄÑо¿±¨¸æ

 
       ¼áÊØ¸ßÖÊÁ¿Éú³¤Ö®Â· £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍøÒ»Ö±ÍÆ¶¯ÖÐʽ×̲¹ÎÄ»¯ÓëÏÖ´ú¿ÆÑÐÈÚºÏÁ¢Òì £¬£¬£¬£¬£¬£¬£¬ÎªÐÐÒµ»À·¢³öȫеÄÉú³¤»îÁ¦¡£¡£¡£¡£¡£Î´À´ £¬£¬£¬£¬£¬£¬£¬WGµç×Ó¹ÙÍø½«¼ÌÐøÆð¾¢ÇóÐÂÇó±ä £¬£¬£¬£¬£¬£¬£¬Éî¶È¹á³¹²úѧÑÐÏàÖú £¬£¬£¬£¬£¬£¬£¬³ä·ÖÍÚ¾òÑàÎѼÛÖµ¡¢¸»ºñ²úÆ·ÀàÐÍ £¬£¬£¬£¬£¬£¬£¬ÎªÖÐʽ×̲¹ÐÐÒµµÄÁ¢Òì¿ªÍØÐÂÆ«Ïò¡£¡£¡£¡£¡£
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿